Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study-Reference-Cited by-同舟云学术

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

Published:2011 Issue:3-4 Volume:80 Page:238-246
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Bruzzone M.,Centurioni M.G.,Giglione P.,Gualco M.,Merlo D.F.,Miglietta L.,Cosso M.,Giannelli F.,Cristoforoni P.,Ferrarini M.

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference38 articles.

1. Treatment goals in ovarian cancer

2. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

3. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial

4. Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorescence Detection of Etoposide Encapsulated Mesoporous Silica Nanoparticles by Environmentally Benign Bioanalytical HPLC Method and its Application to Pharmacokinetic Study;Indian Journal of Pharmaceutical Education and Research;2023-07-23

2. PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin;Cell Reports;2020-01

3. Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach;International Journal of Gynecologic Cancer;2018-10

4. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer;Journal of Obstetrics and Gynaecology;2017-03-21

5. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients;Int. Journal of Clinical Pharmacology and Therapeutics;2015-06-01